The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model

James M. Hill, Ethan M. Stern, Partha S. Bhattacharjee, Daniel Malamud, Christian Clement, Paulo Rodriguez, Walter J. Lukiw, Augusto C. Ochoa, Timothy P. Foster, Cruz Velasco, Harris E. McFerrin

Research output: Contribution to journalArticle

Abstract

The amphoteric C31G solution contains equimolar alkyl dimethlyglycine and alkyl dimethyl amine oxide buffered with citric acid. C31G acts as a broad spectrum antiviral and an antibacterial. No previous in vivo studies have been done to test C31G in an animal model of HSV-1 ocular keratitis. We assessed the anti-herpetic activity of C31G in the rabbit eye model using three treatment groups: (1) 1% trifluorothymidine (TFT); (2) 0.25% C31G plus 0.5% hydroxypropyl methylcellulose (HPMC); and (3) vehicle, 0.5% HPMC. Scarified rabbit corneas were inoculated with the HSV-1 strain McKrae. On post inoculation (PI) day 3, rabbits were placed in three balanced groups based on slit-lamp examination (SLE) scores. Treatment began on PI day 3, five times a day for five consecutive days. In addition to the daily, masked SLE scoring, the eyes were assessed daily for stromal opacity, scleral inflammation, neovascularization, eyelid inflammation, inflammatory discharge, and epiphora. C31G and TFT were very effective in reducing the lesions and pathogenesis associated with HSV-1 ocular keratitis. The vehicle control scores were significantly higher and did not effectively treat HSV-1 keratitis. C31G has the potential to be used to treat herpetic keratitis as well as other herpetic topical lesions in humans.

Original languageEnglish (US)
Pages (from-to)14-19
Number of pages6
JournalAntiviral Research
Volume100
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Keratitis
Human Herpesvirus 1
Anti-Infective Agents
Rabbits
Trifluridine
Therapeutics
Lacrimal Apparatus Diseases
Herpetic Keratitis
Inflammation
Eyelids
C 31G
Citric Acid
Cornea
Oxides
Amines
Antiviral Agents
Animal Models

Keywords

  • Anti-herpetic
  • C31G
  • HSV-1 keratitis
  • Novel anti-herpetic
  • Novel anti-viral
  • Rabbit

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Hill, J. M., Stern, E. M., Bhattacharjee, P. S., Malamud, D., Clement, C., Rodriguez, P., ... McFerrin, H. E. (2013). The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model. Antiviral Research, 100(1), 14-19. https://doi.org/10.1016/j.antiviral.2013.07.002

The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model. / Hill, James M.; Stern, Ethan M.; Bhattacharjee, Partha S.; Malamud, Daniel; Clement, Christian; Rodriguez, Paulo; Lukiw, Walter J.; Ochoa, Augusto C.; Foster, Timothy P.; Velasco, Cruz; McFerrin, Harris E.

In: Antiviral Research, Vol. 100, No. 1, 2013, p. 14-19.

Research output: Contribution to journalArticle

Hill, JM, Stern, EM, Bhattacharjee, PS, Malamud, D, Clement, C, Rodriguez, P, Lukiw, WJ, Ochoa, AC, Foster, TP, Velasco, C & McFerrin, HE 2013, 'The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model', Antiviral Research, vol. 100, no. 1, pp. 14-19. https://doi.org/10.1016/j.antiviral.2013.07.002
Hill, James M. ; Stern, Ethan M. ; Bhattacharjee, Partha S. ; Malamud, Daniel ; Clement, Christian ; Rodriguez, Paulo ; Lukiw, Walter J. ; Ochoa, Augusto C. ; Foster, Timothy P. ; Velasco, Cruz ; McFerrin, Harris E. / The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model. In: Antiviral Research. 2013 ; Vol. 100, No. 1. pp. 14-19.
@article{0b25f6463e5c473384be75d076ac2521,
title = "The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model",
abstract = "The amphoteric C31G solution contains equimolar alkyl dimethlyglycine and alkyl dimethyl amine oxide buffered with citric acid. C31G acts as a broad spectrum antiviral and an antibacterial. No previous in vivo studies have been done to test C31G in an animal model of HSV-1 ocular keratitis. We assessed the anti-herpetic activity of C31G in the rabbit eye model using three treatment groups: (1) 1{\%} trifluorothymidine (TFT); (2) 0.25{\%} C31G plus 0.5{\%} hydroxypropyl methylcellulose (HPMC); and (3) vehicle, 0.5{\%} HPMC. Scarified rabbit corneas were inoculated with the HSV-1 strain McKrae. On post inoculation (PI) day 3, rabbits were placed in three balanced groups based on slit-lamp examination (SLE) scores. Treatment began on PI day 3, five times a day for five consecutive days. In addition to the daily, masked SLE scoring, the eyes were assessed daily for stromal opacity, scleral inflammation, neovascularization, eyelid inflammation, inflammatory discharge, and epiphora. C31G and TFT were very effective in reducing the lesions and pathogenesis associated with HSV-1 ocular keratitis. The vehicle control scores were significantly higher and did not effectively treat HSV-1 keratitis. C31G has the potential to be used to treat herpetic keratitis as well as other herpetic topical lesions in humans.",
keywords = "Anti-herpetic, C31G, HSV-1 keratitis, Novel anti-herpetic, Novel anti-viral, Rabbit",
author = "Hill, {James M.} and Stern, {Ethan M.} and Bhattacharjee, {Partha S.} and Daniel Malamud and Christian Clement and Paulo Rodriguez and Lukiw, {Walter J.} and Ochoa, {Augusto C.} and Foster, {Timothy P.} and Cruz Velasco and McFerrin, {Harris E.}",
year = "2013",
doi = "10.1016/j.antiviral.2013.07.002",
language = "English (US)",
volume = "100",
pages = "14--19",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model

AU - Hill, James M.

AU - Stern, Ethan M.

AU - Bhattacharjee, Partha S.

AU - Malamud, Daniel

AU - Clement, Christian

AU - Rodriguez, Paulo

AU - Lukiw, Walter J.

AU - Ochoa, Augusto C.

AU - Foster, Timothy P.

AU - Velasco, Cruz

AU - McFerrin, Harris E.

PY - 2013

Y1 - 2013

N2 - The amphoteric C31G solution contains equimolar alkyl dimethlyglycine and alkyl dimethyl amine oxide buffered with citric acid. C31G acts as a broad spectrum antiviral and an antibacterial. No previous in vivo studies have been done to test C31G in an animal model of HSV-1 ocular keratitis. We assessed the anti-herpetic activity of C31G in the rabbit eye model using three treatment groups: (1) 1% trifluorothymidine (TFT); (2) 0.25% C31G plus 0.5% hydroxypropyl methylcellulose (HPMC); and (3) vehicle, 0.5% HPMC. Scarified rabbit corneas were inoculated with the HSV-1 strain McKrae. On post inoculation (PI) day 3, rabbits were placed in three balanced groups based on slit-lamp examination (SLE) scores. Treatment began on PI day 3, five times a day for five consecutive days. In addition to the daily, masked SLE scoring, the eyes were assessed daily for stromal opacity, scleral inflammation, neovascularization, eyelid inflammation, inflammatory discharge, and epiphora. C31G and TFT were very effective in reducing the lesions and pathogenesis associated with HSV-1 ocular keratitis. The vehicle control scores were significantly higher and did not effectively treat HSV-1 keratitis. C31G has the potential to be used to treat herpetic keratitis as well as other herpetic topical lesions in humans.

AB - The amphoteric C31G solution contains equimolar alkyl dimethlyglycine and alkyl dimethyl amine oxide buffered with citric acid. C31G acts as a broad spectrum antiviral and an antibacterial. No previous in vivo studies have been done to test C31G in an animal model of HSV-1 ocular keratitis. We assessed the anti-herpetic activity of C31G in the rabbit eye model using three treatment groups: (1) 1% trifluorothymidine (TFT); (2) 0.25% C31G plus 0.5% hydroxypropyl methylcellulose (HPMC); and (3) vehicle, 0.5% HPMC. Scarified rabbit corneas were inoculated with the HSV-1 strain McKrae. On post inoculation (PI) day 3, rabbits were placed in three balanced groups based on slit-lamp examination (SLE) scores. Treatment began on PI day 3, five times a day for five consecutive days. In addition to the daily, masked SLE scoring, the eyes were assessed daily for stromal opacity, scleral inflammation, neovascularization, eyelid inflammation, inflammatory discharge, and epiphora. C31G and TFT were very effective in reducing the lesions and pathogenesis associated with HSV-1 ocular keratitis. The vehicle control scores were significantly higher and did not effectively treat HSV-1 keratitis. C31G has the potential to be used to treat herpetic keratitis as well as other herpetic topical lesions in humans.

KW - Anti-herpetic

KW - C31G

KW - HSV-1 keratitis

KW - Novel anti-herpetic

KW - Novel anti-viral

KW - Rabbit

UR - http://www.scopus.com/inward/record.url?scp=84881141534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881141534&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2013.07.002

DO - 10.1016/j.antiviral.2013.07.002

M3 - Article

VL - 100

SP - 14

EP - 19

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 1

ER -